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Abstract
The intestinal microbiome plays an important role in human health and disease and fecal materials reflect the microbial activity.
Thus, analysis of fecal metabolites provides insight in metabolic interactions between gut microbiota and host organism. In this
work, we applied flow injection analysis coupled to Fourier transform mass spectrometry (FIA-FTMS) to identify and quantify
lipid species in human fecal samples. Fecal homogenates were subjected to lipid extraction and analyzed by FIA-FTMS. The
analysis of different subjects revealed a vast heterogeneity of lipid species abundance. The majority of samples displayed
prominent signals of triacylglycerol (TG) and diacylglycerol (DG) species that could be verified by MS2 spectra. Therefore,
we focused on the quantification of TG andDG.Method validation included limit of quantification, linearity, evaluation ofmatrix
effects, recovery, and reproducibility. The validation experiments demonstrated the suitability of the method, with exception for
approximately 10% of samples, where we observed coefficients of variation higher than 15%. Impaired reproducibility was
related to sample inhomogeneity and could not be improved by additional sample preparation steps. Additionally, these exper-
iments demonstrated that compared with aqueous samples, samples containing isopropanol showed higher amounts of DG,
presumably due to lysis of bacteria and increased TG lipolysis. These effects were sample-specific and substantiate the high
heterogeneity of fecal materials as well as the need for further evaluation of pre-analytic conditions. In summary, FIA-FTMS
offers a fast and accurate tool to quantify DG and TG species and is suitable to provide insight into the fecal lipidome and its role
in health and disease.
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Introduction
It is now generally accepted that the gastrointestinal system in
particular the intestinal microbiome plays an important role in
human health and disease [1]. Microbial activity is reflected in
fecal materials that contain unabsorbed metabolites including
lipid species. Consequently, analysis of fecal metabolites pro-
vides an estimate of metabolic interaction between gut micro-
biota and host [2]. To identify subtle metabolic variations in-
duced by dietary alterations and to characterize the metabolic
impact of variations of the gut microbiota, metabolic profiling
gained increasing interest over the last decade.
Feces are composed of water, proteins, bacterial biomass,
fat, and indigestible food components, e.g., fibers. Fat
contained in feces is a heterogeneous mixture of different
lipids and constitutes 8–16% of the dry weight of feces
[3–5] and 2–8% of wet weight [6–10]. Fat found within feces
comes from bacteria as well as from the undigested remains of
dietary lipids [11]. Approximately 60–70% represents non-/
esterified fatty acids; 20–30% is unsaponifiable material [12].
Human feces contain, depending on diet and metabolism, dif-
ferent amounts of triacylglycerol (TG) and diacylglycerol
(DG), which has been frequently studied in the context of
steatorrhea [13] and colon cancer [14].
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Lipidomic methods nowadays offer a wide range of possi-
bilities to analyze lipid species profiles of biological materials
[15]. However, only a few methods are available to study the
lipidome of fecal material [2, 16, 17]. Most of the described
approaches focus on the identification and quantification of
selected lipid classes like fatty acids [18, 19], bile acids [20],
and sterols [21]. Here, we report the evaluation and validation
of a method for identification and quantification of DG and
TG species of human fecal material using flow injection anal-




Methanol and ethanol absolute (EMSURE) were obtained
from Merck (Darmstadt, Germany), and chloroform and
2-propanol from Roth (Karlsruhe, Germany). All solvents
were of HPLC grade. Ammonium formate was ordered
from Sigma-Aldrich (Taufkirchen, Germany) and isooc-
tane (2,2,4-trimethylpentane) > 99% from Honeywell
(Seelze, Germany). All chemicals and standards were of
high purity grade for analysis (> 95%). Glycerolipid stan-
dards were purchased from Larodan (Solna, Sweden):
diarachidin (DG 20:0/20:0), dinonadecanoin (DG 19:0/
19:0), dilinolenin (DG 18:3/18:3), dilinolein (DG 18:2/
18:2), 1,2-distearin (DG 18:0/18:0), triarachidin (TG
20:0/20:0/20:0), trinonadecanoin (TG 19:0/19:0/19:0),
trilinolein (TG 18:2/18:2/18:2), triolein (TG 18:1/18:1/
18:1), 1,2-olein-3-stearin (TG 18:1/18:1/18:0), 1,2-stea-
rin-3-olein (TG 18:0/18:0/18:1), triheptadecanoin (TG
17:0/17:0/17:0), and tripalmitin (TG 16:0/16:0/16:0).
Purified water was produced by Millipore Milli-Q UF-
Plus water purification system (Molsheim, France).
Stock solutions
All diacylglycerol and triacylglycerol standards were dis-
solved in isooctane/isopropanol (3:1 v/v) with a concen-
tration of 1.0 mg/mL. The internal standard (IS) solution
contained trinonadecanoin, triheptadecanoin, and
diarachidin each at a concentration of 10 μg/mL in
chloroform/methanol (9:1 v/v).
Samples
Human fecal material was obtained from 20 healthy volun-
teers for method development. The material was collected in
the morning and directly transported to the laboratory (stored
on ice). Polypropylene tubes were used for sample collection,
immediately stored at − 20 °C, and transported to the
laboratory on ice. Samples were stored at − 80 °C until further
processing. Samples used to investigate the influence of stool
grade were collected as described by Kjølbæk et al. [22]. This
trial was registered under ClinicalTrials.gov Identifier no.
NCT02215343.
Sample preparation
A randomly selected part of the raw fecal material was ho-
mogenized in isopropanol/water (70/30, v/v) using a
gentleMACS™ Dissociator (Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany) as described previously [21].
The homogenate was diluted in 70% isopropanol to a concen-
tration of 2.0 mg dry weight/mL (dw/mL) for further analysis.
Samples were always kept on ice and stored at − 80 °C until
further processing. An amount of 50 μL of the internal stan-
dard solution (containing 0.54 nmol TG 57:0, 0.59 nmol TG
51:0, and 0.73 nmol DG 40:0) was added to a sample volume
of 100 μL (2 mg dw/mL) fecal homogenate prior to lipid
extraction and extracted according to the protocol of Bligh
and Dyer [23] with a total chloroform volume of 2 mL and
an extraction time of 60min at room temperature. Avolume of
1200 μL of the separated chloroform phase was transferred
into a sample vial by a pipetting robot (Tecan Genesis RSP
150) and evaporated to dryness in a vacuum concentrator. The
residues were dissolved in 1.0 mL chloroform/methanol/2-
propanol (1:2:4 v/v/v) containing 7.5 mM ammonium
formate.
Flow injection Fourier transform mass spectrometry
Mass spectrometric analysis of the reconstituted lipid extracts
was performed by direct flow injection analysis using Fourier
transform mass spectrometry (FIA-FTMS). A hybrid
quadrupole-Orbitrap mass spectrometer (QExactive, Thermo
Fisher Scientific, Bremen, Germany) equipped with a heated
electrospray ionization source was coupled to a PAL
autosampler (CTC Analytics, Zwingen, Switzerland) and an
UltiMate 3000 isocratic pump (Thermo Fisher Scientific,
Waltham, MA, USA). The injection volume was 50 μL and
a solvent mixture of chloroform/methanol/2-propanol
(1:2:4 v/v/v) delivered at an initial flow rate of 100 μL/min
until 0.25 min, followed by 10 μL/min for 2.5 min and a
washout with 300 μL/min for 0.5 min. The ion source was
operated in positive ion mode using the following parameters:
spray voltage 3.5 kV, capillary temperature of 281 °C, S-lens
RF level 55, aux gas heater temperature of 250 °C, and flow
rates of 58 for sheath gas and 16 for aux gas. FTMS data were
recorded in positive ion mode with a maximum injection time
(IT) of 200 ms, an automated gain control (AGC) of 1·106,
three microscans, and a target resolution of 140,000 (at m/z
200). Diacylglycerols were measured in a mass ragem/z 450–
800 and triacylglycerols in a range of m/z 750–1200. MS2
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spectra were acquired for 3 min in mass range m/z 450–1200
with a step size of 1.0008 Da and an isolation window of 1 Da
with a normalized collision energy of 20%, an IT of 64 ms,
AGC of 1·105, and a target resolution of 17,500.
Lipid identification and data processing
ALEX software [24] was used for peak assignment of data
acquired by FTMS and MS/FTMS (MS2) using an m/z toler-
ance of ± 0.0045 Da. Peaks with mass deviation of more than
3 ppm were not considered. Species assignment included
evaluation of product ion spectra (see Electronic
Supplementary Material (ESM) Fig. S2). The assigned data
were exported to Microsoft Excel 2010 and processed using
self-programmed macros. For accurate quantification, intensi-
ties were corrected for type I isotope effects (relative isotope
abundance; [25]). Type II corrections (overlap mainly
resulting from 13C-atoms) were not required at the selected
mass resolution due to peak coalescence (Hoering et al., man-
uscript in preparation). Quantification was performed by nor-
malization of analyte to internal standard intensities multiplied
with the spiked amount of the internal standard as described
recently [26]. Lipids were annotated as sum composition of
acyl chains or without specification of sn positions using “_”
as previously proposed [27].
Method validation
Limit of quantification (LoQ) of DG and TG species was
determined from serial dilutions of fecal samples. Each level
was analyzed in fivefold. The coefficient of variation (CV)
and the absolute value of trueness – 100% were determined
and plotted against the concentrations. The results were fitted
by a power function. LoQ was calculated representing a CVof
≤ 20% and absolute value of trueness – 100% ≤ 20%, respec-
tively. The higher concentration of both calculations was de-
fined as LoQ (for details, see ESM).
Intra-day precision was assessed for five different samples
which were extracted five times and quantified. For inter-day
precision, the same samples were extracted and measured on
five different days (20 days between first and last
measurements).
Linearity of quantification was determined using spiked
samples at six concentration levels. Each level was extracted
5-fold. The results were fitted by a linear function.
Dilution integrity of DG and TG species was deter-
mined by analysis of stool samples at different concentra-
tions (from 1.6 to 0.02 mg dw/mL). Samples were mea-
sured in triplicates. The measured quantity was compared
with the target quantity determined at the highest sample
concentration.
Microscopy
The particle size was documented using phase-contrast mi-
croscopy with × 10 magnification (Zeiss Primovert, Jena,
Germany) and the ZEN 2.6 lite imaging software.
Results and discussion
Our initial aim was to develop an accurate and fast method for
the identification and quantification of lipid species in human
fecal material using FIA-FTMS with a quadrupole-Orbitrap
hybrid mass spectrometer (QExactive). Crude lipid extracts
prepared by chloroform extraction according to the protocol
by Bligh and Dyer [23] were analyzed in positive ion mode.
Upon initial evaluation, spectra revealed a high heterogeneity
(Fig. 1) and numerous peaks could be assigned to [M+NH4]
+
ions of DG and TG species. Other lipid classes were not de-
tected in significant amounts not even in negative ion mode
spectra (data not shown). Therefore, we decided to focus on
the quantification of DG and TG species.
In a first step, 20 different fecal samples were screened for
their DG and TG content. None of the analyzed samples
contained signals representing a relevant interference with
the selected internal standards (IS) DG 40:0, TG 51:0, and
TG 57:0 (ESM Fig. S1). To prove the identity of detected
species, MS2 spectra were evaluated and product ions
assigned according to the annotation system proposed recently
[28] (exemplified in ESM Fig. S2). The concentrations of DG
and TG species detected in these samples span a range up to or
more than three orders of magnitude (Table 1). Highest mean
concentrations were detected for polyunsaturated species with
more than two double bonds: DG 36:3, DG 36:4, TG 54:3, TG
54:4, and TG 54:5. The detected acyl fragments comprised
mainly acyl chains with 16 and 18 carbons and up to three
double bonds. For DG, also species containing FA 12:0 and
14:0 were detected precluding application of DG 28:0 as IS.
Reproducibility
In an important next step within method development [29,
30], we evaluated the performance of the FIA-FTMS method.
Due to sample heterogeneity, intra- and inter-day precisions
were evaluated in five different samples (Tables 2 and 3). The
coefficients of variation (CVs) were below 15% or even below
10% for most DG species. For sample 5 significantly higher
variations were observed especially for TG species concentra-
tions (see also “Evaluation of reproducibility issues”).
Moreover, we observed for this sample a decrease in the con-
centrations of most of the TG species from day to day. Despite
storage of the samples in 70% isopropanol at − 80 °C, this
decline may be related to lipase activity since enzymatic ac-
tivity has been reported also in organic solvents [31, 32].

































































































































Fig. 1 Displayed are mass spectra
from three individual human fecal
samples analyzed in positive ion
mode. Panel a shows the mass
range of DG species (m/z 500–
720) and panel b of TG species
(m/z 810–980)
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Limit of quantification
Higher CV values were most likely related to concentrations
close to limit of detection. Therefore, limits of quantification
(LoQs) were determined functionally as described previously
[21, 33]. Non-endogenous DG and TG species were spiked at
various concentrations and analyzed in 5-fold. CV and accu-
racy were fitted as shown in Fig. S3 (see ESM). The calculated
LoQs were in the range of 0.01–0.2 nmol/mg dw for DG
species and 0.01–0.3 nmol/mg dw for TG species. LoQs de-
termined at CV of 20% were significantly lower compared
with those determined by accuracy. Most of the LoQs derived
from CVs were in the range of 0.01 to 0.02 nmol/mg dw
which also matched the inter- and intra-day CVs listed in
Tables 2 and 3. This demonstrates a reproducible analysis
below 0.1 nmol/mg dw. LoQs derived from accuracy analysis
Table 1 Concentrations and acyl combinations of DG and TG species in human feces from 20 different samples. Data based on a single measurement
of the individual samples and acyl combinations were derived from MS2 spectra
Compound [M+NH4]
+ m/z Mean ± standard deviation (nmol/mg dw)* Median Min Max Acyl combinations
DG 26:0 502.447 0.139 ± 0.348 0.004 n.d. 1.401 DG 12:0_14:0
DG 28:0 530.478 0.080 ± 0.214 0.002 n.d. 0.919 DG 12:0_16:0
DG 14:0_14:0
DG 30:0 558.509 0.106 ± 0.322 0.008 n.d. 1.454 DG 12:0_18:0
DG 14:0_16:0
DG 34:3 608.525 0.428 ± 0.660 0.240 n.d. 2.808 DG 16:0_18:3
DG 34:2 610.541 1.865 ± 1.856 0.994 0.045 6.198 DG 16:0_18:2
DG 34:1 612.556 0.776 ± 0.711 0.503 0.068 2.417 DG 16:0_18:1
DG 36:5 632.525 1.254 ± 1.922 0.726 0.002 8.481 DG 18:2_18:3
DG 36:4 634.541 7.305 ± 8.349 4.302 0.053 32.355 DG 18:2_18:2
DG 18:1_18:3
DG 36:3 636.556 4.371 ± 4.513 2.452 0.042 14.508 DG 18:1_18:2
DG 36:2 638.572 3.632 ± 4.283 2.564 0.074 17.947 DG 18:1_18:1
DG 18:0_18:2
TG 48:0 824.770 0.042 ± 0.104 0.010 n.d. 0.491 TG 16:0_16:0_16:0
TG 50:3 846.755 0.475 ± 0.465 0.445 0.018 1.008 TG 16:0_16:1_18:2
TG 50:2 848.770 0.141 ± 0.253 0.072 0.003 1.150 TG 16:0_16:0_18:2
TG 16:0_16:1_18:1
TG 50:1 850.786 0.083 ± 0.116 0.032 0.006 0.430 TG 16:0_16:0_18:1
TG 50:0 852.801 0.164 ± 0.466 0.031 n.d. 2.088 TG 16:0_16:0_18:0
TG 52:5 870.755 0.105 ± 0.143 0.045 n.d. 0.566 TG 16:1_18:2_18:2
TG 16:0_18:2_18:3
TG 52:4 872.770 0.841 ± 1.284 0.494 n.d. 5.869 TG 16:0_18:2_18:2
TG 16:1_18:1_18:1
TG 52:3 874.786 0.487 ± 0.901 0.174 n.d. 3.666 TG 16:0_18:1_18:2
TG 52:2 876.801 0.459 ± 0.892 0.127 0.009 3.465 TG 16:0_18:1_18:1
TG 16:0_18:0_18:2
TG 53:4 886.786 0.269 ± 0.270 0.234 0.005 0.624 TG 17:1_18:1_18:2
TG 54:9 890.723 0.078 ± 0.160 0.003 n.d. 0.641 TG 18:3_18:3_18:3
TG 54:7 894.755 0.409 ± 0.528 0.080 n.d. 1.895 TG 18:2_18:2_18:3
TG 54:6 896.770 1.238 ± 1.721 0.684 n.d. 7.388 TG 18:0_18:3_18:3
TG 18:1_18:2_18:3
TG 18:2_18:2_18:2
TG 54:5 898.786 1.174 ± 1.886 0.599 0.003 7.875 TG 18:1_18:2_18:2
TG 54:4 900.801 1.175 ± 2.250 0.422 0.003 8.988 TG 18:1_18:1_18:2
TG 18:0_18:1_18:3
TG 54:3 902.817 1.523 ± 3.239 0.294 0.008 11.560 TG 18:1_18:1_18:1
TG 18:0_18:1_18:2
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depend on accurate addition of low amounts of DG/TG spe-
cies, which may be compromised by many factors including
analyte absorption or inhomogeneity issues (described be-
low). Except a poor curve fit as a factor, we could not find
an explanation for the order of magnitude difference between
the LoQs determined for different species. There seems to be
neither a relation to species chain length nor number of double
bonds. LoQs for DG and TG appear to be similar. Based on
these considerations, we applied for practical reasons
0.02 nmol/mg dw as LoD and 0.1 nmol/mg dw as LoQ (this
is also substantiated by data from dilution integrity testing
shown below).
Recovery, linearity, and dilution integrity
Recovery of DG and TG species was determined at two spike
levels (ESM Table S1). Most of the determined recoveries
were within the expected range of 85 to 115%. However,
considering the high complexity of fecal material as matrix,
we think that recoveries between 75 and 135% are acceptable.
Table 2 Coefficient of variation (CV) of intra- and inter-day precision of DG species determined in five different human fecal samples by FIA-FTMS/
MS analyzed in fivefold
Diacylglycerols Intra-day CV (%) Inter-day CV (%)
Sample Mean (n = 5) (nmol/mg dw) Mean (n = 5) (nmol/mg dw)
DG 34:3 Sample 1 0.13 7.2 0.13 11.6
Sample 2 0.36 16.0 0.38 13.7
Sample 3 0.61 6.4 0.63 8.1
Sample 4 0.59 3.7 0.53 4.3
Sample 5 0.12 24.1 0.12 15.3
DG 34:2 Sample 1 1.45 2.7 1.48 6.4
Sample 2 3.37 16.2 3.53 13.4
Sample 3 4.32 6.3 4.43 7.0
Sample 4 7.55 1.6 4.79 4.5
Sample 5 1.81 2.6 1.75 6.4
DG 34:1 Sample 1 1.87 3.6 1.92 7.2
Sample 2 0.67 15.1 0.69 14.8
Sample 3 1.85 7.2 1.89 7.7
Sample 4 5.66 1.9 5.16 2.1
Sample 5 0.36 30.5 0.33 13.9
DG 36:5 Sample 1 0.29 6.6 0.29 10.3
Sample 2 1.09 16.4 1.14 13.2
Sample 3 1.69 5.7 1.74 8.2
Sample 4 0.05 21.0 0.05 43.1
Sample 5 0.40 4.5 0.38 7.2
DG 36:4 Sample 1 4.32 3.2 4.38 7.5
Sample 2 10.99 16.2 11.50 13.2
Sample 3 14.31 6.3 14.68 7.3
Sample 4 13.20 2.3 11.92 4.0
Sample 5 5.95 9.6 5.90 9.3
DG 36:3 Sample 1 5.89 2.3 5.98 6.1
Sample 2 5.82 14.0 6.04 11.6
Sample 3 11.29 6.9 11.61 8.1
Sample 4 43.50 2.0 39.27 3.9
Sample 5 2.89 4.6 2.75 5.6
DG 36:2 Sample 1 10.27 2.2 10.43 6.2
Sample 2 2.38 14.4 2.48 11.7
Sample 3 6.50 7.7 6.65 7.9
Sample 4 53.49 2.2 48.53 3.2
Sample 5 1.9 3.2 1.83 5.5
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Table 3 Coefficient of variation (CV) of intra- and inter-day precision of TG species determined in five different human fecal samples by FIA-FTMS/
MS analyzed in fivefold
Triacylglycerols Intra-day CV (%) Inter-day CV (%)
Sample Mean (n = 5) (nmol/mg dw) Mean (n = 5) (nmol/mg dw)
TG 50:2 Sample 1 0.07 5.4 0.07 8.9
Sample 2 0.13 10.5 0.14 15.7
Sample 3 4.15 7.1 4.15 7.4
Sample 4 3.50 10.4 3.17 9.9
Sample 5 0.19 97.3 0.11 118.3
TG 50:1 Sample 1 0.17 1.9 0.18 12.1
Sample 2 0.07 18.5 0.07 20.4
Sample 3 1.26 5.8 1.26 5.9
Sample 4 1.01 10.5 0.92 9.9
Sample 5 0.06 69.9 0.04 82.1
TG 50:0 Sample 1 0.22 10.5 0.24 20.1
Sample 2 0.05 14.9 0.05 14.1
Sample 3 n.d. n.d. n.d. -
Sample 4 n.d. n.d. n.d. -
Sample 5 0.10 7.4 0.10 9.9
TG 52:5 Sample 1 n.d. n.d. n.d. -
Sample 2 0.11 7.3 0.11 10.7
Sample 3 3.41 7.8 3.49 11.9
Sample 4 2.10 8.9 1.91 8.5
Sample 5 n.d. n.d. n.d. -
TG 52:4 Sample 1 0.32 5.9 0.32 14.2
Sample 2 0.82 7.6 0.84 11.6
Sample 3 27.90 6.9 27.76 7.8
Sample 4 20.26 9.4 18.36 9.0
Sample 5 1.25 87.4 0.66 116.8
TG 52:3 Sample 1 0.39 9.0 0.41 16.2
Sample 2 0.44 13.5 0.46 13.4
Sample 3 18.36 5.1 18.30 5.9
Sample 4 65.61 10.4 59.35 10.1
Sample 5 0.35 23.6 0.37 140.5
TG 52:2 Sample 1 1.04 11.1 1.09 14.8
Sample 2 0.21 10.5 0.22 13.5
Sample 3 9.74 4.9 9.77 6.0
Sample 4 45.75 10.8 41.29 10.5
Sample 5 0.35 92.8 0.18 129.3
TG 54:7 Sample 1 n.d. n.d. n.d. -
Sample 2 0.24 7.1 0.24 9.8
Sample 3 14.67 8.6 15.10 14.7
Sample 4 0.21 13.9 0.19 13.4
Sample 5 n.d. n.d. n.d. -
TG 54:6 Sample 1 0.35 6.0 0.38 28.8
Sample 2 1.24 9.7 1.27 11.0
Sample 3 51.78 5.6 51.45 6.7
Sample 4 20.86 9.2 18.89 8.9
Sample 5 1.40 74.4 0.77 104.8
TG 54:5 Sample 1 0.82 9.5 0.85 18.9
Sample 2 1.41 10.9 1.45 10.9
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To further evaluate the dynamic range of the method, the
linearity of quantification was tested for several species not
present in fecal samples. DG 36:6, DG 38:0, TG 54:2, and TG
54:1 were spiked at six different concentrations (ESM Fig.
S4). All species revealed a good correlation of spiked and
detected concentrations. However, species response seems to
depend on structural features, as described for cholesteryl es-
ter [26], and should be studied in detail in further studies. A
linear range covering most of the tested samples was demon-
strated up to 120 mg dw/mL and 90 mg dw/mL for DG and
TG, respectively.
Moreover, dilution integrity was tested by quantification of
gradually diluted stool samples (1.6 to 0.02 mg dw/mL). Low
(DG 32:0, TG 48:0), medium (DG 34:2, TG 52:2), and high
(DG 36:3, TG 54:4) abundant species showed a good corre-
lation of expected and measured concentrations (ESM Fig.
Table 3 (continued)
Triacylglycerols Intra-day CV (%) Inter-day CV (%)
Sample Mean (n = 5) (nmol/mg dw) Mean (n = 5) (nmol/mg dw)
Sample 3 52.48 4.1 52.47 5.6
Sample 4 106.95 10.4 96.83 10.0
Sample 5 1.85 102.5 0.92 146.0
TG 54:4 Sample 1 1.83 11.6 1.89 15.3
Sample 2 0.93 11.0 0.96 11.6
Sample 3 37.41 4.1 37.39 5.7
Sample 4 175.39 10.5 146.61 26.1
Sample 5 0.65 28.9 0.66 147.5
TG 54:3 Sample 1 4.78 11.3 4.91 14.2
Sample 2 0.44 12.0 0.46 12.8
Sample 3 18.69 4.2 18.72 5.8
Sample 4 248.23 12.4 225.33 11.5
Sample 5 0.6 88.8 0.29 131.0
Table 4 DG and TG concentrations and their coefficient of variation (n = 5) related to stool grading
Diacylglycerol Triacylglycerol
sample Mean (n = 5) (nmol/mg dw) CV (%) Mean (n = 5) (nmol/mg dw) CV (%)
Grade 1 Sample a 46.11 6.6 2.31 11.6
Sample b 15.71 7.6 14.25 6.1
Sample c 54.27 6.4 8.55 10.7
Grade 2 Sample d 78.73 7.1 10.69 10.9
Sample e 38.65 26.3 82.10 27.6
Sample f 11.62 2.1 1.11 20.8
Grade 3 Sample g 93.86 9.2 38.27 10.2
Sample h 27.30 6.0 2.65 7.5
Sample i 29.44 6.5 39.34 5.1
Grade 4 Sample j 52.35 3.0 5.15 7.9
Sample k 14.30 5.8 1.87 6.5
Sample l 21.41 2.7 2.15 2.5
Grade 5 Sample m 66.36 6.4 15.67 6.0
Sample n 25.91 8.9 19.96 8.0
Sample o 94.64 4.2 11.83 5.5
Grade 6 Sample p 65.84 4.8 10.28 5.6
Sample q 44.92 3.8 21.40 5.2
Sample r 49.10 17.0 39.42 15.2
Grade 7 Sample s 46.94 22.2 1.74 18.6
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S5). The assay was linear at low (DG 32:0 and TG 48:0) and
high concentrations (DG 36:3, TG 54:4) and matched the
above described LoQ and LoD and linear range (up to
250 mg DG dw/mL and 150 mg TG dw/mL), respectively.
Evaluation of reproducibility issues
As described above, very high variations were observed for
some samples (about 10% of tested fecal samples). Therefore,
various experiments were performed to evaluate the origin of
irreproducibility. Despite thorough mechanical homogeniza-
tion, fecal samples are suspensions and a lack of homogeneity
may cause variations. Therefore, we first tested whether cen-
trifugation affects DG and TG concentrations. Five samples
showing high variations were analyzed without centrifugation
as well as after centrifugation (ESM Table S2). While DG
species were detected in both pellet and supernatant, TG spe-
cies were found in three of the samples enriched in the pellet.
However, the DG/TG species profiles of supernatant and pel-
let closely resembled each other (ESM Table S3), suggesting
that centrifugation does not separate a specific pool of these
lipid classes.
In order to improve the homogeneity, we tested addition of
detergent (0.1%, 0.5%, and 1.0% SDS), an additional homog-
enization step using the Precellys® homogenizer (data not
shown) as well as sonication up to 3 h (ESM Table S4). All
of these additional treatments did not result in a decrease of
variation. In contrast, the application of higher sample vol-
umes (2 mg instead of 200 μg dw) for lipid extraction showed
some decrease of CV, especially for TG species and samples
with a high fraction of TG in the pellet. Considering that
variation is mainly due to sample inhomogeneity, drawing a
higher sample volume could explain lower variations.
In a next step, we asked whether these inhomogeneity is-
sues could be related to the consistency of the fecal material.





Fig. 2 Effect of isopropanol addition on DG (a) and TG (b)
quantification. Displayed are six individual samples homogenized in
water and supplemented with the same volume of either H2O (brown)
or isopropanol (green) (70% related to volume)
Fig. 3 Comparison of human fecal sample D diluted either in water (a) or
in isopropanol (b) at a dry weight of 2 mg dw/mL using phase-contrast
microscopy with × 10 magnification
Quantification of diacylglycerol and triacylglycerol species in human fecal samples by flow injection... 2323
stool grade (according to Bristol Stool Chart [34]; with grade 1
representing hard and grade 7 watery consistency) from a
study on fiber and polyunsaturated fatty acid interventions
[22]. The samples were measured in five replicates
(Table 4). Samples with grades 3 to 5 showed CVs ≤ 10%.
However, in samples with lower grades (1 to 2), we could
not see a clear trend for higher CVs, which may have been
expected for more solid consistency.
Finally, we checked whether the solvent used for sample
preparation may affect DG/TG concentrations. In several stud-
ies, homogenization of fecal material was performed not only in
water [35] or aqueous buffer [36, 37], but also in diluted organic
solvents [38, 39]. In our laboratory, diluted isopropanol was
used to stabilize fecal concentrations of short chain fatty acids
[40]; thus, the effect of isopropanol was investigated for DG/
TG concentrations. Therefore, fecal raw material was homoge-
nized in water and subsequently diluted at ratios of 3 to 7 (by
volume) with either water or isopropanol (Fig. 2) and immedi-
ately stored at − 80 °C. Unexpectedly, addition of isopropanol
tremendously increased DG concentrations in almost all sam-
ples. Moreover, in two of the six samples, we observed a drop
of TG concentrations. However, the increase of DG could not
be explained by TG degradation in these samples because the
increase of DG exceeded the decreased amount of TG.
Comparison of spectra of samples stabilized in water or
isopropanol showed clear differences in all DG species profiles
and in the TG profiles of three of the six samples (ESM
Table S5). We could not observe additional species upon
isopropanol addition and no common pattern in the increased
DG species for the individual samples.
To get more insight, we examined both aqueous and
isopropanol-containing sample homogenates by light micros-
copy (Fig. 3). Clearly, aqueous samples seem to be more ho-
mogeneous compared with isopropanol-containing samples.
However, in aqueous samples, a massive presence of bacteria
could be observed. To inhibit metabolic activity and to reduce
health risks, fecal samples are frequently treated with alcohols.
Currently, we cannot explain the aggregation induced by ad-
dition of isopropanol. The increase of DG upon isopropanol
addition seems to be related to both disruption of bacteria
resulting in improved extractability of DG and lipolysis of
TG. The latter seems to be triggered in some samples by
addition of isopropanol and matches lipolytic activities ob-
served in organic solvents [31, 32]. These data clearly dem-
onstrate that further studies are warranted to evaluate optimal
pre-analytic conditions for fecal samples as well as the origin
of these differences.
Conclusion
Here we report, to our knowledge, the first method for the
identification and quantification of DG and TG in human fecal
material using FIA coupled to a high-resolution FTMS instru-
ment. Up to now, only a few studies on the fecal lipidome exist
which is most likely related to the difficulties faced with this
sample material [2, 16]. The proposed method has a short run
time of 4 min per sample, including MS2 measurements, fa-
cilitating a high sample throughput necessary for clinical stud-
ies. Validation of the novel method demonstrated its suitability
for large-scale studies despite the higher variations observed
for some samples. These variations are related to inhomoge-
neity of samples and lipolytic activity that requires further
investigations considering pre-analytical issues as an essential
part of lipidomic workflows and their standardization [29, 30,
41]. Therefore, we recommend performing measurements in
triplicate, when high accuracy is needed. In this regard, sam-
pling is very important since metabolites are distributed highly
heterogeneous in feces and homogenization of larger quanti-
ties is recommended [42].
In summary, the presented method provides a valuable tool
to quantify DG and TG species, the major lipid classes in
human fecal samples. These data could be a first step to un-
ravel the fecal lipidome and get more insight into its role for
health and disease.
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